关注免疫检查点抑制剂诱导的内分泌系统免疫相关不良事件

Pay attention to immune-related adverse events induced by immune checkpoint inhibitors

免疫检查点抑制剂(ICI)是目前备受瞩目的肿瘤免疫治疗药物,在多种恶性肿瘤的治疗中取得较为显著的疗效。但ICI也可诱发一系列免疫相关不良事件(irAE),以内分泌系统irAE较为常见,发生率约为40%,对患者原发疾病的治疗和生活质量有显著影响,甚至可能危及生命。建议从进一步加强irAE发生机制研究、诊断与鉴别诊断研究以及多学科诊疗团队建设、对接受ICI治疗的肿瘤患者进行全流程管理等方面提高内分泌系统irAE的诊治水平。

Immune checkpoint inhibitors(ICI)is a class of high-profile immunotherapy drugs for tumor,which has showed remarkable efficacy in the treatment of a variety of malignant tumors.However,ICI can also induce a series of immune-related adverse events(irAE),which are common in endocrine system with an incidence of about 40%.The irAE in endocrine system has obvious impacts on the efficacy of ICI for primary diseases and quality of life in patients,which may even be life-threatening.It is suggested that the diagnosis and treatment of irAE in endocrine system should be improved through further strengthening the research on the mechanism,diagnosis,and differential diagnosis of irAE,constructing multidisciplinary teams on diagnosis and treatment,and performing whole process management of tumor patients treated with ICI.